Source: Hematology, Transfusion and Cell Therapy. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, MUTAÇÃO GENÉTICA, EXPRESSÃO GÊNICA, SEQUENCIAMENTO GENÉTICO, CITOCINAS, INFLAMAÇÃO
ABNT
MACEDO, Brunno Gilberto Santos et al. A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy, v. 47, n. 2, p. 7 , 2025Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2025.103758. Acesso em: 22 maio 2025.APA
Macedo, B. G. S., Melo, M. A. de, Pereira-Martins, D. A., Traina, F., & Machado Neto, J. A. (2025). A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy, 47( 2), 7 . doi:https://doi.org/10.1016/j.htct.2025.103758NLM
Macedo BGS, Melo MA de, Pereira-Martins DA, Traina F, Machado Neto JA. A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 7 .[citado 2025 maio 22 ] Available from: https://doi.org/10.1016/j.htct.2025.103758Vancouver
Macedo BGS, Melo MA de, Pereira-Martins DA, Traina F, Machado Neto JA. A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 7 .[citado 2025 maio 22 ] Available from: https://doi.org/10.1016/j.htct.2025.103758